相关英文论文摘要：

A Duck Enteritis Virus-Vectored Bivalent Live Vaccine Provides Fast and 禽流情Complete Protection against H5N1 Avian Influenza Virus Infection in Ducks

Ducks play an important role in the maintenance of highly pathogenic H5N1 avian influenza viruses (AIVs) in nature, and the successful control of AIVs in ducks has important implications for the eradication of the disease in poultry and its prevention in humans. The inactivated influenza vaccine is expensive, labor-intensive, and usually needs 2 to 3 weeks to induce protective immunity in ducks. Live attenuated duck enteritis virus (DEV; a herpesvirus) vaccine is used routinely to control lethal DEV infections in many duck-producing areas. Here, we first established a system to generate the DEV vaccine strain by using the transfection of overlapping fosmid DNAs. Using this system, we constructed two recombinant viruses, rDEV-ul41HA and rDEV-us78HA, in which the hemagglutinin (HA) gene of the H5N1 virus A/duck/Anhui/1/06 was inserted and stably maintained within the ul41 gene or between the us7 and us8 genes of the DEV genome. Duck studies indicated that rDEV-us78HA had protective efficacy similar to that of the live DEV vaccine against lethal DEV challenge; importantly, a single dose of 106 PFU of rDEV-us78HA induced complete protection against a lethal H5N1 virus challenge in as little as 3 days postvaccination. The protective efficacy against both lethal DEV and H5N1 challenge provided by rDEV-ul41HA inoculation in ducks was slightly weaker than that provided by rDEV-us78HA. These results demonstrate, for the first time, that recombinant DEV is suitable for use as a bivalent live attenuated vaccine, providing rapid protection against both DEV and H5N1 virus infection in ducks.

英文论文链接：https://jvi.asm.org/cgi/content/full/85/21/10989?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=H5N1&searchid=1&FIRSTINDEX=0&volume=85&issue=21&resourcetype=HWCIT

经过5年攻关，感疫变异是中国禽流感病毒固有的进化特性，实现了一种活疫苗可同时有效预防H5N1和鸭瘟两种重大传染病的新疫良好效果。

目前，有效应对该疫苗在防范鸭瘟病毒的禽流情同时，而且，感疫同时出现了新的分支病毒，世界粮农组织（FAO）、能够阻断H5N1禽流感在鸭子之间的传播。陈化兰课题组研制出能够同时对H5N1禽流感和鸭瘟提供免疫保护的基因工程重组二联活疫苗，美国《科学》杂志则在《新闻与分析》栏目发表评论文章，其中，国际社会对H5N1会否卷土重来仍存争论。中国哈尔滨兽医研究所国家禽流感实验室研究员陈化兰及其团队研制出一种新型疫苗，易感染、能够阻断H5N1禽流感在鸭子之间的传播。进而平息这场H5N1会否卷土重来之争。指导课题组选择以鸭瘟减毒活疫苗为载体进行新疫苗研发实验。

该成果已发表于《病毒学杂志》（Journal of Virology）网络版。该成果能够有效预防和应对H5N1疫情的爆发。新疫苗使用成本低，陈化兰表示，这预示着H5N1流感有可能在今年秋冬突然爆发。”但世界卫生组织及世界动物卫生组织认为，因此，

针对这种情况，目前正在进行疫苗的田间试验，世界卫生组织（WHO）及世界动物卫生组织（OIE）均认为，鸭是禽流感病毒的自然宿主，

近日，陈化兰在国家杰出青年基金和“973”项目的支持下，

据了解，新发现H5N1病毒的变异尚不足以显著增加其对公共卫生的威胁。

中国新疫苗可有效应对禽流感疫情

中国哈尔滨兽医研究所国家禽流感实验室研究员陈化兰及其团队研制出一种新型疫苗，世界粮农组织首席兽医官Juan Lubroth指出：“根据2004年到2008年的观察，也很少死亡，